Form 4: Amylyx Pharmaceuticals Director Trades Common Stock

Amylyx Pharmaceuticals Director Karen Firestone reported a transaction involving the acquisition of 3,800 shares of common stock.

Summary

• Director Karen Firestone acquired 3,800 shares of Amylyx Pharmaceuticals common stock on May 21, 2026.
• The acquisition was made at a price of $13.51 per share.
• Following this transaction, Firestone beneficially owns 66,900 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine disclosure of a director's stock transaction without additional context on the company's performance or strategic direction.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The purchase of 3,800 shares at $13.51 per share indicates a belief in the current valuation or undervaluation of the stock.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings, such as this one from Amylyx Pharmaceuticals, are standard disclosures for insider transactions and are closely watched by investors for signals of management's confidence in the company's performance and valuation.

Stakeholder Impact

• Shareholders may interpret this director's purchase as a positive signal of confidence in the company's stock.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Form 4, Insider Trading, Director Transaction, Common Stock, Beneficial Ownership